Immune-Based Drug Combo Might Extend Cancer Survival
MONDAY, April 2 (HealthDay News) — Cancer patients who receive a combination of low-dose interleukin-2 and retinoic acid after conventional therapy seem to live longer than those who don’t get the combination.